• SPX
  • $5,958.25
  • 0.16 %
  • $9.54
  • DJI
  • $44,088.14
  • 0.5 %
  • $217.78
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,267.16
  • 1.45 %
  • $117.89
  • IXIC
  • $18,961.90
  • -0.06 %
  • -$10.52
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News & Analysis

Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.15

$0.05

(2.55%)

Day's range
$2.15
Day's range
$2.2
50-day range
$1.98
Day's range
$2.96
  • Country: US
  • ISIN: US04216R1023
52 wk range
$1.98
Day's range
$4.48
  • CEO: Dr. Deborah L. Birx M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -6.64
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (ARMP)
  • Company Armata Pharmaceuticals, Inc.
  • Price $2.15
  • Changes Percentage (2.55%)
  • Change $0.05
  • Day Low $2.15
  • Day High $2.20
  • Year High $4.48

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/13/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.20
  • Trailing P/E Ratio -1.24
  • Forward P/E Ratio -1.24
  • P/E Growth -1.24
  • Net Income $-69,045,000

Income Statement

Quarterly

Annual

Latest News of ARMP

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Armata Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of ARMP in the last quarter?

    In the last quarter Armata Pharmaceuticals, Inc. earnings were on Wednesday, November, 13th. The Armata Pharmaceuticals, Inc. maker reported -$0.15 EPS for the quarter, beating analysts' consensus estimates of -$0.28 by $0.13.

  • What is the Armata Pharmaceuticals, Inc. stock price today?

    Today's price of Armata Pharmaceuticals, Inc. is $2.15 — it has increased by +2.55% in the past 24 hours. Watch Armata Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Armata Pharmaceuticals, Inc. release reports?

    Yes, you can track Armata Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Armata Pharmaceuticals, Inc. stock forecast?

    Watch the Armata Pharmaceuticals, Inc. chart and read a more detailed Armata Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Armata Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on AMEX, exchange stock trades by Armata Pharmaceuticals, Inc. stock ticker.

  • How to buy Armata Pharmaceuticals, Inc. stocks?

    Like other stocks, ARMP shares are sold on stock exchanges such as AMEX. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Armata Pharmaceuticals, Inc.'s EBITDA?

    Armata Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Armata Pharmaceuticals, Inc.’s financial statements.

  • What is the Armata Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -15.2450872157, which equates to approximately -1,524.51%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Armata Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Armata Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Armata Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Armata Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Armata Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.